<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01706874</url>
  </required_header>
  <id_info>
    <org_study_id>2011- AO1271 - 40</org_study_id>
    <nct_id>NCT01706874</nct_id>
  </id_info>
  <brief_title>Effect Assessment of Periodontal Prophylaxis on Rheumatoid Arthritis Activity.</brief_title>
  <acronym>BHYRRA</acronym>
  <official_title>Assessment of the Effect of an Intervention (Periodontal Scaling + Mouthwash + Toothpaste) to Reduce the Load on Oral Bacterial Activity of Rheumatoid Arthritis: a Randomized Trial Nested in the Cohort ESPOIR</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Société Française de Parodontologie et d'Implantologie Orale (SFPIO)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the impact of an intervention (scaled every 06 months&#xD;
      associated with the use of mouthwash with essential oils (toothpaste and Listerine® 2 times /&#xD;
      day containing polymer Triclosan (Colgate Total®)) on the activity of rheumatoid arthritis&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Introduction: Several epidemiological studies have suggested that a link between periodontal&#xD;
      disease and rheumatoid arthritis. In cohorts, the risk of development of rheumatoid arthritis&#xD;
      is increased in subjects with periodontal disease. The main bacterium implicated in chronic&#xD;
      periodontal disease is Porphyromas gingivalis, a commensal microorganism of the mouth. P.&#xD;
      gingivalis is the only microorganism with a deiminase capable of transforming arginine into&#xD;
      citrulline, and is suspected of to play a major role in the production of anti-citrulline&#xD;
      antibodies, the principal diagnostic marker of rheumatoid arthritis.&#xD;
&#xD;
      Hypotheses: The regular professional and individual plaque control in patients with&#xD;
      rheumatoid arthritis (standard of care) - i.e. decreasing oral bacterial load, including P.&#xD;
      gingivalis - reduces the activity of rheumatoid arthritis Principal objective: To assess the&#xD;
      impact of professional periodontal scaling every 6 months combined with the individual plaque&#xD;
      control, i.e. toothbrushing plus the use of mouthrinses on rheumatoid arthritis activity.&#xD;
&#xD;
      Methodology: The trial design is innovative and based on random selection of a sample of&#xD;
      patients in an observational cohort of patients as described in the recent publication&#xD;
      &quot;Cohort Multiple Randomised Controlled Trials Design&quot; (Ref.: BMJ 2010; 340: c1066). A&#xD;
      randomly selected sample of eligible patients from the cohort will be asked to take part in&#xD;
      the study. Changes in the randomised sample will be compared to those of other potentially&#xD;
      eligible patients from the cohort. The cohort used will be the ESPOIR cohort, a cohort&#xD;
      including 813 patients who initially presented with early undifferentiated polyarthritis that&#xD;
      developed into rheumatoid arthritis with anti-citrulline antibodies in approximately 40 to&#xD;
      50% of cases.&#xD;
&#xD;
      Procedures studied: Periodontal scaling every 6 months and twice daily use of a mouthwash&#xD;
      containing essential oils (Listerine®) plus a triclosan/copolymer toothpaste (Colgate&#xD;
      Total®).&#xD;
&#xD;
      Sample size calculation: The principal assessment criterion is DAS variations at 1 year. The&#xD;
      expected statistical power is 80% (the type I risk being set at 5%) and the standard&#xD;
      deviation common to the two samples for DAS variation is evaluated at 1.5. With these&#xD;
      hypotheses, the inclusion of 100 patients in the study group and 100 patients in the control&#xD;
      group will produce an effect size of 0.40 (i.e. a difference in DAS between the two groups&#xD;
      equal to 0.6).&#xD;
&#xD;
      Statistical analysis: A linear, mixed-effects model will be used to compare DAS variations&#xD;
      between the two groups. In addition, the Mixed Model for Repeated Measurements (MMRM) based&#xD;
      on a linear mixed model will include two other random effects, i.e.: the centre effect and&#xD;
      the centre*treatment interaction effect, which will be used to measure heterogeneity between&#xD;
      the centres and heterogeneity of the effect of the procedure. Finally, propensity scores with&#xD;
      adjustment by weighting will be used to take into account any potential imbalances between&#xD;
      the two study arms.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 20, 2012</start_date>
  <completion_date type="Actual">July 26, 2017</completion_date>
  <primary_completion_date type="Actual">September 7, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Periodontal prophylaxis</measure>
    <time_frame>at 12 months</time_frame>
    <description>Assessment of the effect of an intervention : periodontal prophylaxis (periodontal scaling + mouthwash + toothpaste)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bacterial identification</measure>
    <time_frame>at 12 months</time_frame>
    <description>Assessment of the effect of an intervention: Bacterial identification. A bacterial sampling at 4 deepest periodontal pockets will be carried.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease activity score (DAS) 28</measure>
    <time_frame>at 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of anti-citrulline and anti P. gingivalis antibodies</measure>
    <time_frame>at 12 months</time_frame>
    <description>Evaluate the impact of this intervention on the rate of anti-citrulline and anti P. gingivalis antibodies. A bacterial sampling at 4 deepest periodontal pockets will be carried.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">92</enrollment>
  <condition>Anti-CCP Positive Early Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Periodontal prophylaxis</arm_group_label>
    <description>Periodontal prophylaxis (standard of care) versus control in rheumatoid arthritis patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Periodontal prophylaxis (standard of care) versus control in rheumatoid arthritis patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Periodontal prophylaxis</intervention_name>
    <description>Periodontal scaling (every 6 months) plus mouthrinses plus toothbrushing (twice daily). Removal of adherent plaque and calculus with ultrasonic instruments and hand instruments, such as periodontal scalers and curettes, and polishing of the teeth</description>
    <arm_group_label>Periodontal prophylaxis</arm_group_label>
    <other_name>Mouthrinse: Listerine®; toothpaste: Colgate Total®</other_name>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Biospecimen: gingival fluid&#xD;
&#xD;
      A first sampling will take place at T0 and the second at Month 12 (test end).&#xD;
&#xD;
      A bacterial sampling at 4 deepest periodontal pockets will be carried. It will quantify the 9&#xD;
      following bacteria:&#xD;
&#xD;
      Aggregatibacter actinomycetemcomitans Porphyromonas gingivalis Prevotella intermedia&#xD;
      Tannerella forsythensis Treponema denticola Peptostreptococcus micros Fusobacterium nucleatum&#xD;
      Eikenella corrodens Campylobacter rectus&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Population selected from the ESPOIR early arthritis Cohort&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with rheumatoid arthritis according to EULAR criteria / ACR 2010 under 10&#xD;
             years of evolution&#xD;
&#xD;
          -  Patients included in the ESPOIR cohort&#xD;
&#xD;
          -  Patients with DAS28 &gt; 3.2&#xD;
&#xD;
          -  Anti-CCP positive and negative&#xD;
&#xD;
          -  Age: 18 years old to 80 years&#xD;
&#xD;
          -  Affiliated to social security&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Refusal to participate in the study&#xD;
&#xD;
          -  DAS28 &lt; 3.2&#xD;
&#xD;
          -  Patient under guardianship&#xD;
&#xD;
          -  Participation in another protocol without agreement of the dentist&#xD;
&#xD;
          -  Not affiliated to social security&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xavier MARIETTE, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Paris-Sud University, AP-HP</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philippe BOUCHARD, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Paris Diderot University, AP-HP</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philippe RAVAUD, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Paris Descartes University, AP-HP</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Rotschild - Service d'Odontologie</name>
      <address>
        <city>Paris</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>September 14, 2012</study_first_submitted>
  <study_first_submitted_qc>October 12, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 15, 2012</study_first_posted>
  <last_update_submitted>July 31, 2017</last_update_submitted>
  <last_update_submitted_qc>July 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Rheumatoid arthritis</keyword>
  <keyword>P.gingivalis</keyword>
  <keyword>Periodontal disease</keyword>
  <keyword>Plaque control</keyword>
  <keyword>Prophylaxis</keyword>
  <keyword>Oral hygiene instruction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Listerine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

